SWOG Cancer Research Network

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, SWOG Cancer Research Network sits in the top decile of US sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count).

270 total trials 28 currently recruiting 181 completed early-phase tilt top decile by trial count

SWOG Cancer Research Network: 270 sponsored US clinical trials, 28 recruiting.

SWOG Cancer Research Network sponsors 270 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 181 completed. 68 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.

Top-decile sponsor footprint

SWOG Cancer Research Network ranks in the top decile of sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

181 of 221 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

270 total, page 6 of 6

COMPLETED Phase 2

S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00002969

COMPLETED Phase 3

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

NCT00002920

TERMINATED Phase 2

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

NCT00002921

COMPLETED

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900

COMPLETED Phase 2

SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma

NCT00002860

COMPLETED Phase 2

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

NCT00002849

TERMINATED Phase 3

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

NCT00002772

TERMINATED Phase 2

SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue

NCT00002735

COMPLETED Phase 2

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

NCT00002665

COMPLETED Phase 2

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

NCT00002657

COMPLETED Phase 2

SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00002642

COMPLETED Phase 3

S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed

NCT00002593

COMPLETED Phase 2

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

NCT00002571

COMPLETED

SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease

NCT00002563

COMPLETED Phase 3

SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

NCT00002551

COMPLETED Phase 3

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

NCT00002548

COMPLETED

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

NCT00898872

COMPLETED Phase 3

SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease

NCT00002495

COMPLETED

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

NCT00996047

COMPLETED

SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

NCT00900484

← Previous Page 6 of 6

What is open in the SWOG Cancer Research Network pipeline

28 recruiting of 270 indexed (10% open); 181 completed (67%).

Phase mix: 68 late (III/IV) vs 164 early (I/II) (early-phase heavy).

Top condition: Lung Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

SWOG Cancer Research Network: open-pipeline peers nationwide

Peers matched on 270 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300 0%5%10%15% Total trials Recruiting share SWOG Cancer Research NetworkAlcon ResearchNovartisAbbott Medical DevicesBoston Scientific CorporationCalifornia Pacific Medical Center Research InstituteNational Institute of Environmental Health Sciences (NIEHS)University of Rhode IslandUniversity of Mississippi Medical Center
SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 270 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this SWOG Cancer Research Network page

270 registered trials is a research-attention snapshot, not an endorsement of SWOG Cancer Research Network or any single study.

  • 28 of SWOG Cancer Research Network's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lung Cancer is the condition SWOG Cancer Research Network studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. SWOG Cancer Research Network pipeline card: 270 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.